Entry level $8.00 = Target price $9.75 = Stop loss $7.50
Possible long term breakout in the stock which has made a nice recovery on the back of earnings surprise.
It's possible it may consolidate for a few days on the market weakness.
Average analysts price target $13 | BUY rating
High 14% short interest
Company profile
Aurinia Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of a therapeutic drug to treat autoimmune diseases particularly lupus nephritis. The company was founded by Robert Foster, Richard Glickman and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada.
Possible long term breakout in the stock which has made a nice recovery on the back of earnings surprise.
It's possible it may consolidate for a few days on the market weakness.
Average analysts price target $13 | BUY rating
High 14% short interest
Company profile
Aurinia Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of a therapeutic drug to treat autoimmune diseases particularly lupus nephritis. The company was founded by Robert Foster, Richard Glickman and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada.
Comment:
Comment:
apologies it went up 120% not 22 BOOOOMMMMMMM